Altogether, our results showing an increased CD16/Granzyme B-positive cell infiltration after murlentamab infusion and very few NK cells at the tumor site (in all biopsies tested, less than 0.1% of cells were positive with a staining using an anti-NKp46 antibody) suggest a monocyte/macrophage-dependent anti-tumor mechanism. The gene discussed is NCR1; the disease is neoplasm.